Alnylam Canada Signs Letter of Intent From Pan-Canadian Pharmaceutical Alliance for the Public Reimbursement of Amvuttra® for the Treatment of Hereditary Transthyretin-Mediated (Hattr) Amyloidosis in Adults
Alnylam Canada與泛加拿大藥品聯盟簽署意向書，用於向成人公衆報銷Amvuttra®治療遺傳性前轉鐵蛋白介導（Hattr）澱粉樣變性。
